Financial Review: Atrion (ATRI) vs. Intersect ENT (XENT)
Atrion (NASDAQ:ATRI) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.
Volatility and Risk
Atrion has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
61.7% of Atrion shares are held by institutional investors. Comparatively, 97.5% of Intersect ENT shares are held by institutional investors. 22.5% of Atrion shares are held by insiders. Comparatively, 5.9% of Intersect ENT shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Atrion pays an annual dividend of $5.40 per share and has a dividend yield of 0.6%. Intersect ENT does not pay a dividend. Atrion has raised its dividend for 16 consecutive years.
This is a breakdown of current recommendations for Atrion and Intersect ENT, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intersect ENT has a consensus target price of $39.00, indicating a potential upside of 36.41%. Given Intersect ENT’s higher probable upside, analysts plainly believe Intersect ENT is more favorable than Atrion.
This table compares Atrion and Intersect ENT’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Atrion and Intersect ENT’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atrion||$152.45 million||10.91||$34.26 million||N/A||N/A|
|Intersect ENT||$108.47 million||8.12||-$22.92 million||($0.76)||-37.62|
Atrion has higher revenue and earnings than Intersect ENT.
Atrion beats Intersect ENT on 10 of the 14 factors compared between the two stocks.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
About Intersect ENT
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.